Real-world Evidence on Baseline Characteristics and Treatment in Metastatic Hormone-sensitive Prostate Cancer: Findings from the PIONEER 2.0 Big Data Investigation Group

In this study of nearly 70 000 men with metastatic hormone-sensitive prostate cancer, doctors' treatment decisions were influenced strongly by patients' age and other health issues, highlighting a growing preference for combination therapies. The findings highlight the importance of real-world evidence, which captures diverse, often under-represented, patients to complement clinical trials and guide more inclusive, evidence-based care.